Roderich
Süssmuth
a,
Jane
Müller
a,
Hans
von Döhren
b and
István
Molnár
*cd
aTechnische Universität Berlin, Institut für Chemie, Strasse des 17. Juni 124, 10623, Berlin, Germany. E-mail: suessmuth@chem.tu-berlin.de; Fax: (+49) 030-314-79651
bTechnische Universität Berlin, AG Biochemie und Molekulare Biologie, Franklinstrasse 29, 10587, Berlin, Germany
cSW Center for Natural Products Research and Commercialization, Office of Arid Lands Studies, School of Natural Resources and the Environment, The University of Arizona, 250 E. Valencia Rd., Tucson, AZ 85706, USA. E-mail: imolnar@cals.arizona.edu
dBio5 Institute, The University of Arizona, 1657 E. Helen Str., Tucson, AZ 85721, USA
First published on 20th October 2010
Covering: up to the end of August 2010
This review surveys the biological activities and the iterative and recursive biosynthetic mechanisms of fungal cyclooligomer depsipeptides, and their structural diversification by various combinatorial biosynthetic methods.
![]() Roderich Süssmuth | Roderich Süssmuth is the Rudolf Wiechert Professor of Biological Chemistry at TU Berlin. He obtained his Ph.D. degree in chemistry in 1999 from the Eberhard Karls Universität Tübingen with Günther Jung. In 2000, he was a Feodor-Lynen-Fellow of the Alexander von Humboldt-Foundation with Carlos Barbas III and Richard Lerner. Subsequently he became an Assistant Professor in Tübingen with an Emmy-Noether fellowship granted by the DFG, and then moved in 2004 to TU Berlin. His research is focused on antibiotics, biosynthetic assembly lines, enzymes and enzyme inhibitors. |
![]() Jane Müller | Jane Müller received her Master's degree (Diploma) in chemistry from the Technical University in Berlin. During that time she worked in the group of Dr. Rainer Zocher on the enzymatic synthesis of new cyclodepsipeptides as potential drug candidates. She is currently a Ph.D. student in the laboratory of Roderich Süssmuth at TU Berlin and works on the heterologous expression of cyclodepsipeptide synthetases. |
![]() Hans von Döhren | Hans von Döhren received his doctoral degree at TU Berlin with Horst Kleinkauf in 1977, characterizing the structure of gramicidin S synthetase. As a postdoc he initiated work on the applications of peptide synthetases and multienzyme structure–-function analysis. From 1983 to the present, he has been a lecturer in biochemistry. His research has focused on peptide biosynthesis, with the current main topics being in the areas of mechanisms of amino acid activation and peptide bond formation, β-lactam antibiotics and fungal peptide diversity, and cyanobacterial toxins. |
![]() István Molnár | István Molnár studied molecular biology at the ELTE University (Budapest, Hungary) before joining the Institute for Drug Research in Budapest to investigate antibiotic biosynthesis in actinomycetes. He went on to conduct graduate studies in microbial sterol transformations (Ph.D. 1993 with Prof. Yoshikatsu Murooka at Hiroshima University, Japan), and postdoctoral research on the biosynthesis of rapamycin (1994–1997 with Prof. Peter Leadlay at Cambridge University, UK). As a staff scientist, and later group leader and principal scientist for Syngenta Biotechnology (formerly Novartis Agribusiness), North Carolina, he worked on the biosynthesis of epothilone and soraphen, and the biocatalytic production of emamectin. Since 2004, he has been an Associate Professor at the Natural Products Center of the University of Arizona, studying fungal polyketide and nonribosomal peptide biosynthesis. His research interests include the engineering of natural product biosynthetic pathways for drug discovery and development, and biofuels research. |
The tremendous structural variety of nonribosomal peptides is based on the flexibility of the biosynthetic programming of the NRPS: the utilization of non-proteinogenic amino acid precursors (more than 300 described); the formation of main-chain heterocycles (thiazole, oxazole and their derivatives); and the construction of linear, macrocyclic or branched macrocyclic structures with amide, ester or even thioester or imino ring closures.4,8 In the scaffold of the nonribosomal depsipeptides, at least one bond of the peptide backbone is replaced by an ester bond: these connect carboxy groups of amino acids with a 2-hydroxycarboxylic acid, or provide alternative routing of the chain via side chain hydroxy groups of amino acids and the C-terminus of the peptide. The structural complexity of nonribosomal (depsi)peptides is further enhanced by the installation of N-terminal aryl or alkyl caps, lipid or glycosyl side chains, and the formation of intramolecular bridges (disulfide bridges, oxidative coupling between side chains), as catalyzed by “decorating” enzymes.9
Cyclooligomer nonribosomal peptides consist of oligopeptide or, in the case of cyclooligomer depsipeptides (CODs), oligopeptidol monomer units that undergo recursive head-to-tail condensation, or oligomerization via side chains, followed by macrocyclization.8 The corresponding NRPSs form a subclass of Type B NRPSs. These NRPSs use their modules iteratively for the biosynthesis of several copies of identical or nearly identical peptide/peptidol monomer units that remain covalently bound on the enzyme. These enzymes also evolved mechanisms for the recursive, stepwise intermolecular ligation and final intramolecular cyclization of the monomer units in a concerted cyclooligomerization process.
Fungal CODs, the subject of the current review, are privileged pharmacophores that display a wide variety of bioactivities, including antibiotic, insecticidal, anthelminthic, herbicidal, anti-retroviral, cytotoxic, anti-haptotactic, and chemosensitizer activities, as well as inhibition of cholesterol biosynthesis, and repression of amyloid plaque formation in Alzheimer's disease. Fungal COD biosynthesis has been characterized first by isolating and reconstituting active cyclooligomer depsipeptide synthetase (CODS) enzymes from the producer fungi, and later by isolating, characterizing and heterologously expressing the encoding synthetase genes. New fungal CODS genes were discovered by genome mining, and interesting mechanistic differences were noted for CODS of fungal versus bacterial origin. Novel analogs of fungal CODs have been generated by a variety of combinatorial biosynthetic methods, including precursor-directed biosynthesis, mutasynthesis, combinatorial mutasynthesis, and total biosynthesis.
Cyclodepsipeptides showing a pseudo-cyclodimeric structure have also been isolated from several Dothiodeomycete Pithomyces spp. (teleomorph: Leptosphaerulina spp.). The cyclotetradepsipeptide angolide12 (5) and the cyclohexadepsipeptide sporidesmolides13 (6) are apparent dimers of a dipeptidol (angolide) or a tripeptidol (sporidesmolides). However, the exclusive utilization of D amino acids in one half of these molecules, and L amino acids in the other half, argues against their origin from cyclodimerization (see Section 4.9).
Beauvericin is toxic to brine shrimp and to the larvae of insects,16,21 and acts as an important virulence factor during insect pathogenesis by B. bassiana.22 It also displays moderate antifungal activity, and antibiotic activity against Gram-positive bacteria.21 Beauvericin is a low-micromolar inhibitor of acyl CoA:cholesterol acyltransferase (ACAT, EC 2.3.1.26): inhibition of this enzyme leads to decreased plasma cholesterol levels.23,24 ACAT inhibition also suppresses proteolytic processing of the β-amyloid precursor protein, thereby reducing amyloid plaque density in animal models of Alzheimer's disease.25,26 A recent publication showed that beauvericin, as well as enniatin I and enniatin MK 1688, exhibit strong in vitro inhibitory activity against the type-1 human immunodeficiency virus (HIV-1) integrase, but not against the Moloney murine leukemia virus reverse transcriptase.27
Beauvericin also reverses the multidrug-resistance (MDR) phenotype in yeast and potentiates the fungicidal activity of fluconazole against fluconazole-resistant Candida albicans at concentrations that are not directly fungicidal.28–30 Synergistic activities amongst different antibiotics are well known (i.e. streptogramin A and B components), but compounds that show only weak antibiotic or antifungal activity themselves might also increase the potency of bona fide antibiotics or antifungals. These potentiators or sensitizers might prevent the inactivation of the antibiotic or antifungal agents, and facilitate the penetration or inhibit the active efflux of these agents through the cell envelopes of the pathogens.31
Beauvericin was also shown to act as a potentiator of cytotoxic drugs in multidrug-resistant (MDR) cancer cell lines. Overexpression of P-glycoprotein (Pgp), an ABC superfamily transporter, is a prominent cause of multidrug resistance in human cancers. Beauvericin was shown to directly bind to purified Pgp with an apparent KD of 0.36 µM, and to inhibit the drug transport function of Pgp in membrane vesicle preparations at 1 µM. Beauvericin restored daunorubicin accumulation in the Pgp-overexpressing MDR Chinese hamster ovarian cell line CHRC5 at sub-cytotoxic concentrations.32
Beauvericin displays potent cytotoxic activity against different human cell lines.33 Beauvericin increases cytoplasmic Ca2+ concentration, causes ATP depletion, and activates calcium-sensitive cell apoptotic pathways.34,35 At sub-cytotoxic concentrations, beauvericin inhibits the haptotactic motility of cancer cells.36 Formation of new blood vessels in tumors (angiogenesis), tissue invasion by cancer cells, and metastasis all involve haptotaxis (directional cell motility).37 In contrast, haptotaxis is rather infrequent in adults under ordinary physiological conditions.38 Inhibition of angiogenesis is a validated cancer chemotherapeutic strategy as shown by thalidomide and bevacizumab, and is one of the established mechanisms of action of the marketed drugs sunitinib, sorafenib, and paclitaxel.39,40 Inhibition of tissue invasion and metastasis might restrain new tumor formation, or increase successful containment of solid tumors. The cytotoxic and the anti-haptotactic activities of the taxanes41 and the Vinca alkaloids42 have distinct mechanisms of actions.
The purity of the enzyme preparations was monitored by in vitro formation of CODs upon supply of substrates (amino acid and hydroxycarboxylic acid), Mg2+, ATP and SAM. The common reaction times were up to one hour at 25 °C, usually with complete loss of activity. The half lives of the enzyme preparations were found to be diverse, ranging from 12 h at 0 °C for the PF1022 synthetase61 to 50 h at 25 °C for the enniatin synthetase.83 Generally, protease content was a limiting factor, and proteinase inhibitors were found to be essential for stabilization (H. Peeters, Doctoral Thesis, TU Berlin, 1988). Reported catalytic activities range from 2 pkat mg−1 (beauvericin synthetase) and 12 pkat mg−1 (PF1022 synthetase) to 100 pkat mg−1 for the enniatin synthetase. This highest activity corresponds to a turnover number of 2 catalytic cycles/min.
3 AA + 3 HA + 3 SAM + 6 ATP → COD + 6 AMP + 6 PPi + 3 SAH | (1) |
The stoichiometry of the overall reaction in relation to the requirement of 1 mole ATP per peptide or ester bond formed has not been proven so far, but can be assumed based on analogous studies in penicillin biosynthesis.85 The binding stoichiometry of the required methylation cofactor could be determined as 1 mole SAM per mole FeESYN.86 Reconstitution routinely involves optimization of each of the substrate concentrations, with the determination of apparent Km values. A complete kinetic description of such complex systems has not been achieved yet. The reaction cycle is considered irreversible, as COD hydrolysis is not observed under normal conditions. However, as partial reactions are indeed reversible (see below), byproducts such as PPi and SAH act as inhibitors of enniatin synthesis. In this context, Zocher and coworkers showed that SAH acts as a non-competitive inhibitor with respect to the substrates L-Val, D-Hiv and ATP.86 Upon omission of SAM, N-desmethyl enniatins are obtained at about a ten-fold lower synthesis rate (kcat 0.13 s−1 for enniatin, kcat 0.019 s−1 for desmethyl enniatin).79,86 Likewise, limited SAM concentrations lead to the synthesis of partially demethylated enniatin analogs.
The overall kinetic parameters of ESYN from Fusarium oxysporum ETH 1536/9 were determined from double reciprocal plots.86 The Km values of ATP, L-Val and D-Hiv were determined to be 350 µM, 80 µM and 5 µM, respectively, and did not differ significantly in the presence of SAH. The Km value of SAM was measured to be 10 µM, which is in the range of other methyltransferases.87 At higher SAH concentrations, the synthesis of desmethyl enniatins was suppressed, in contrast to a continued, albeit decreased enniatin synthesis. This indicates that SAH only has an effect on the rate of COD synthesis, but not on substrate binding, and hence seems to interfere with elongation or product cyclization. From these findings, it can be surmised that suppression of desmethyl enniatin synthesis by SAH may have a regulatory role on enniatin synthesis in vivo. This hypothesis is supported by the finding that desmethyl enniatins are rarely found in fermentation broths, while they are produced during enniatin synthesis in vitro.86
COD formation can be detected by a colorimetric picrate assay following extraction of mycelia, broth or assay mixtures,88 or quantified by radioactively labeled SAM or amino acids.84,86 COD analogs may be separated by TLC or HPLC. More recently electrospray mass spectrometry (ESI-MS) combined with MS/MS fragmentation has been established as an alternative and more precise method for the detection and quantitation of enniatins,89 as well as of PF1022-analogs.90
Using the enniatin synthetase as a model, the enzymatic reconstitution of the 350 kDa PF1022 synthetase was also achieved, and PF1022 congeners were produced in vitro with the substrates L-Leu, D-Lac, D-PheLac, Mg2+, SAM and ATP.61 The Km values for product formation were determined to be Km(D-Lac) = 0.77 ± 0.15 µM; Km(D-PheLac) = 0.45 ± 0.12 µM; and Km(L-Leu) = 20 ± 3 µM. In this in vitro approach, it was not only possible to detect all of the naturally occurring PF1022 congeners by mass spectrometry, but the rarely-occurring truncated hexa- and tetradepsipeptides were also observed. The later compounds were predicted to result from premature release from the PF1022 synthetase.
To clone the beauvericin and the bassianolide biosynthetic genes from the hypocrealean entomopathogen Beauveria bassiana ATCC 7159, Xu et al.22,57 designed several different pairs of degenerate PCR primers against the conserved A3 and A8 motifs of NRPS A domains.92 Some of these primers were heavily biased towards the D-Hiv-activating A domains of the F. equiseti enniatin synthetase (FeESYN).91 Enniatins, similar to beauvericin and bassianolide, contain D-Hiv as their 2-hydroxycarboxylic acid constituents. Amongst the PCR products amplified using B. bassiana total DNA as a template, two distinct amplicons showed high sequence similarity to FeESYN. Fosmids from a genomic DNA library of B. bassiana that hybridized to these amplicons as probes were shown to derive from two disparate genomic loci. Sequencing revealed that each of these loci encodes one enniatin synthetase-like CODS. These CODSs were separately knocked out, and several isolates of the strains with the disrupted CODS genes, as well as ectopic integrants, were fermented under beauvericin/bassianolide production conditions. Ectopic integrants produced both beauvericin and bassianolide at wild-type yields. Production of beauvericin was abrogated in the BbBEAS knockout strains, while BbBSLS knockouts were unable to produce bassianolide.22,57
The XsBSLS bassianolide synthetase of the wood-decaying fungus Xylaria sp. BCC1067 was identified by a PCR-based NRPS genome scanning strategy.55 One of the NRPS-encoding amplicons was used as a probe to clone a CODS-encoding genomic locus from a λ phage genomic library. The nrpsxy gene encoding this CODS was disrupted on the chromosome of Xylaria sp. by directed gene knockout. Comparison of the metabolic profiles of the mycelial extracts of the wild-type and the mutant strains revealed the production of bassianolide in the wild-type strain, and the abrogation of production of this COD in the knockout strain.55 Prior to this work, bassianolide production had not been described outside the hypocrealean entomopathogens Beauveria and Verticillium.
The RsPFSYN PF1022 synthetase gene (BD013055) was cloned from the unidentified fungus Mycelia sterilia.93 This ‘Fungus imperfectus’, classified later as Rosellinia sp., was isolated from the plant Camellia japonica in Japan.94
Two sequences of putative CODSs are also available from GenBank, although the CODs that these synthetases produce have not been experimentally established. ADB27871 is derived from Fusarium oxysporum FB1501, a strain that produces both beauvericin and the enniatins H, I and MK 1688.19 AAY73200 is present in F. venenatum ATCC20334, a producer of enniatin B.95 Further genome mining has identified a putative CODS (FOXG_11847) in F. oxysporum f. sp. lycopersici, a producer of enniatins. The current gene model for this CODS ends prematurely at a contig gap, and therefore the encoded CODS is a truncated protein with approximately 140 amino acids missing from the C-terminus. Two additional putative CODS were also found by genome mining from Trichoderma sp.: TRIVE1.E_GW1.16.170.1 from T. virens, and TRIAT1.E_GW1.1.2949.1 from T. atroviridae. To the best of our knowledge, no COD has been isolated from either of these Trichoderma species to date.
All identified CODS, regardless of producing hexa- or octadepsipeptides, display the same extended bimodular architecture with an identical domain arrangement: C1A1T1–C2A2M2T2aT2b–C3 (Fig. 1). The only exception is the XsBSLS bassianolide synthetase from Xylaria sp. which has an additional “reductase” domain attached at its C-terminus (see Section 5.1).
![]() | ||
Fig. 1 Biosynthesis of CODs. |
The A1 domain of the first module of the CODSs activates the D-2-hydroxycarboxylic acid substrate and loads it onto the T1 domain in the same module, as shown experimentally in the case of the loading of D-Hiv onto the enniatin synthetase.96,97 The A2 domain of the second module activates and loads an L-amino acid substrate molecule onto each of the adjacent twin T2 domains. The second module also features an N-methyltransferase domain (M2) which is inserted into the A2 domain between core motifs A8 and A9.86 The flexible loop between these motifs often accommodates different editing domains in various NRPSs.98,99 The SAM-dependent N-methyltransferase tailoring domains of NRPSs82,86 modify the T domain-bound aminoacyl thioesters prior to condensation by the adjacent C domain,100,101 and were first described and characterized from CODSs.82,86
Amide bond formation between the D-2-hydroxycarboxylic acid and N-Me-amino acid thioesters is carried out by the C2 domain. NRPS C domains were shown to form several phylogenetic clades corresponding to functional subtypes.102 Although the C2 domains of CODS catalyze a condensation between substrates of D and an L configuration (i.e. they are formally DCL domains), their core motifs are nevertheless more similar to domains of the LCL subtype.102DCL condensation domains evolved to perform a gating function to select upstream substrates of the D configuration from the racemic mixtures generated by the preceding E domains. CODS A1 domains however specifically activate only the D enantiomer of the 2-hydroxycarboxylic acid substrate,97 thus the C2 domains do not have to select their substrates, nor do they have to interact with E domains. Peptide bond formation between the two substrates generates the dipeptidol monomer, three or four copies of which would then be ligated and finally cyclized in a programmed cyclooligomerization process to generate the cyclohexadepsipeptide or cyclooctadepsipeptide products, respectively.
This deduced assignment is based not only on the colinearity rule of NRPS organization, but is also supported by both limited proteolysis data and information from the expression of CODS fragments.96,97 During the purification of the enniatin synthetase from Fusarium scirpi, endogenous proteolysis was observed, and two main fragments of 200 and 105 kDa were purified.97 The 200 kDa fragment, comprising the C1A1T1C2 domains, catalyzed hydroxycarboxylic acid adenylation as well as its attachment to the T domain as a thioester. A similar fragment was also obtained from the F. sambucinum enniatin synthetase. As the N-terminus was presumably blocked, the N-terminal location of this fragment within the synthetase was inferred from monoclonal antibody (mAb) binding.103 The 105 kDa fragment did not show catalytic activity, and was mapped by mAb-binding and N-terminal sequencing to the central region, comprising C2 and a segment of A2. Active site radiolabeling of ESYN and its fragments with substrates, followed by V8 protease digestion and HPLC separation, identified fragments containing the A1T1 didomain for hydroxycarboxylic acid attachment, and the M2T2aT2b domains for amino acid attachment. Both types of fragments were also shown to contain pantetheine as a required cofactor. Likewise, the SAM-binding site has been localized by radiolabeling and chymotryptic digestion to the M2-region.97
The heterologous expression of various CODS fragments comprising the regions C1A1T1 (121 kDa), A2M2T2aT2b (158 kDa) and M2 (65 kDa) of the FeESYN ennitatin synthetase has been achieved in E. coli.96 Catalytic activities of adenylate formation have been demonstrated by D-Hiv and L-Val dependent ATP-PPi-exchange. Activation of non-cognate substrates was also detected, but this did not exceed 15 to 20% of that with the cognate substrates. As misincorporation varied depending on the fragment size for the A2-containing fragments, this promiscuity may be an artefact of improper folding. SAM binding by the regions containing the M2 domain has also been validated by photolabeling with 14C-SAM.
A1 + HA + ATP ⇆ A1(HA–AMP) + PPi | (2a) |
A2 + AA + ATP ⇆ A2(AA–AMP) + PPi | (2b) |
These activation reactions have been demonstrated by substrate-dependent ATP–PPi exchange, relying on the reverse reaction to generate labelled ATP from radiolabelled PPi and the acyl adenylate intermediate.104
Structure-guided alignments of bacterial A domain sequences can be used to predict the residues that line the substrate binding pocket of these enzymes. The predicted amino acid residues can then be used to predict the substrate specificity of the A domains of novel bacterial NRPSs, relying on comparisons with a large database of A domains with known substrate specificities.3,105,106 A 10-amino acid “specificity code” (the “non-ribosomal code”) is routinely used for these predictions.105 This non-ribosomal code has recently been extended to a set of 34 amino acid residues, modeled to lie within a distance of 8 Å around the substrate.107
In contrast to A domains in bacterial NRPS enzymes, an a priori prediction of substrate specificity is currently not possible in fungal NRPS A domains. The substrate specificity signature motifs or “specificity codes” are divergent from those of bacteria, and there is a relative lack of A domains with known substrate specificities from fungal sources. Substrate predictions in CODS are thus very imprecise, and even “postdictions” (deriving consensus codes based on product structures) are somewhat equivocal.
Synthetaseb | Domain | Specificityc | 235d | 236 | 239 | 278 | 299 | 301 | 322 | 330 | 331 | 517 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
a Amino acids identical to those in the proposed fungal A domain consensus signature are shown in white font on black background. Amino acids similar (V = I = L; A = G, S = T, W = Y = F) to those in the proposed A domain consensus signature are shown in bold type over a gray background. b NRPS abbreviations: BbBEAS, Beauveria bassiana beauvericin synthetase;22 BbBSLS, B. bassiana bassianolide synthetase;57 FeESYN, Fusarium equiseti enniatin synthetase;91 FoCODS, F. oxysporum cyclooligomer depsipeptide synthetase (ADB27871); FolCODS, F. oxysporum f. sp. lycopersici cyclooligomer depsipeptide synthetase (FOXG_11847); FvCODS, F. venenatum cyclooligomer depsipeptide synthetase (AAY73200); RsPFSYN, Rosellinia sp. PF1022 synthetase (BD013055); TaCODS, Trichoderma atroviridae cyclooligomer depsipeptide synthetase (TRIAT1.E_GW1.1.2949.1); TvCODS, T. virens cyclooligomer depsipeptide synthetase (TRIVE1.E_GW1.16.170.1); XsBSLS, Xylaria sp. bassianolide synthetase.55 c A domain specificities: D-Hiv, D-2-hydroxyisovalerate; PheLac/Lac, D-phenyllactate and D-lactate. d Amino acid numbering according to the A domain of PheA.105,106 e Fungal D-Hiv signature as proposed previously.22 | ||||||||||||
Fungal D-Hiv signaturee |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
||
BbBEAS | A1 | D-Hiv |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
BbBSLS | A1 | D-Hiv |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
XsBSLS | A1 | D-Hiv |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
FeESYN | A1 | D-Hiv |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
FvCODS | A1 | ? |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
FolCODS | A1 | ? |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
FoCODS | A1 | ? |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
TaCODS | A1 | ? |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
TvCODS | A1 | ? |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
RsPFSYN | A1 | PheLac/Lac |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Synthetaseb | Domain | Specificityc | 235d | 236 | 239 | 278 | 299 | 301 | 322 | 330 | 331 | 517 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
a Amino acids identical to those in the proposed fungal A domain consensus signature are shown in white font on a black background. Amino acids similar (V = I = L; A = G, S = T, W = Y = F) to those in the proposed A domain consensus signature are shown in bold type over a gray background. b FsESYN, Fusarium sambucinum enniatin synthetase;81 see Table 1 for further NRPS abbreviations. c A domain specificities: Val/Leu/Ile, valine preferred, leucine and isoleucine also accepted; Ile/Leu/Val, isoleucine preferred, leucine and valine also accepted. d Amino acid numbering according to the A domain of PheA105,106 e Fungal Leu signature, as proposed previously.57 | ||||||||||||
Fungal Leu signaturee |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
||
XsBSLS | A2 | Leu |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
RsPFSYN | A2 | Leu |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
TaCODS | A2 | ? |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
TvCODS | A2 | ? |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
BbBSLS | A2 | Leu |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
FoCODS | A2 | ? |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
BbBEAS | A2 | Phe |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
FeESYN | A2 | Val/Leu/Ile |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
FvCODS | A2 | ? |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
FolCODS | A2 | ? |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
FsESYN | A2 | Ile/Leu/Val |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
In a comparative analysis of purified enniatin synthetases from Fusarium scirpi, F. sambucinum and F. lateritium, amino acid specificities were analyzed by estimation of catalytic constants from product formation.81 The most efficient synthesis was found with L-Val for the F. scirpi enzyme, L-Ile and L-Leu for the F. sambucinum enzyme, and L-Val for the F. lateritium enzyme. These trends are exactly what one would expect from the compositions of the enniatin congener mixtures produced by these strains in vivo.
A1(HA–AMP) + T1SHp1 → T1–Sp1–HA + AMP + A1 | (3a) |
A2(AA–AMP) + T2SHp2 → T2–Sp2–AA + AMP + A2 | (3b) |
Comparison of the T1 and twin T2 carrier domains show a relatively high primary sequence divergence. Both T2 domains might interact with the adjacent N-methyl-transferase domain to facilitate N-methylation of the amino acid intermediate (reaction (4)). The twin T2 domains contain more highly conserved charged residues than the T1 domains, presumably to facilitate multiple docking events with the A, M and C domains, assuming that the primary docking events of these domains rely on electrostatic interactions. In one model proposed for cyclooligomerization in fungal CODS (see below), only the T2a domain anchors the amino acid and its N-methyl intermediate, while the T2b domain serves as a “waiting position” that holds the resulting dipeptidol intermediate while this awaits cyclooligomerization.110 This scheme implies a lack of interaction between T2b and A2 and M2.
T2–Sp2–AA + SAM → T2–Sp2NMeAA + SAH | (4) |
It is presently unknown if both of the twin carrier domains, or only the closely associated T2a domain interact with the M2 domain. The M2 domain of the enniatin synthetase from Fusarium scirpi has been mapped by both protein chemical methods and fragment expression. The 49 kDa protein has been expressed in Saccharomyces cerevisiae with an N-terminal hexahistidine tag and a C-terminal streptavidin II fusion peptide.100 Contacts with the substrate SAM have been assigned by saturation transfer difference (STD) NMR spectroscopy. Catalytic activity has been demonstrated with L-aminoacyl-N-acetylcysteamine thioesters (aminoacyl-SNACs) of substrate-related amino acids. Km values of L-Val-SNAC and SAM were similar for enniatin synthetase and the expressed fragment, thus indicating correct folding.
In an analysis of methyltransferase domains of multifunctional PKS and NRPS systems of both bacterial and fungal origin, Ansari et al.111 have shown that N-, O-and C-methyltransferase sequences from distinct subgroups. Structure-guided sequence alignments led to the identification of structural motifs in M2 domains that are similar to those in non-integrated methyl transferases.112
T1–Sp1–HA + T2–Sp2–NMeAA → T1–SHp1 + T2–Sp2–NMeAA–HA | (5) |
The isolation of the dipeptidol reaction intermediate shows that the peptide bond is formed first,84 followed later by the ester bond-forming condensation and cyclization reactions. The production of the diketomorpholine bassiatin (9) from the beauvericin producer Beauveria bassiana, and the isolation of cyclo(Lac-MeLeu) and cyclo(PheLac-N-Me-Leu) from the PF1022-producer Rosellinia sp. (W. Weckwerth, Doctoral Thesis, TU Berlin, 1998) indicate that some dipeptidols may undergo an early cyclization reaction, instead of being used for cyclooligomerization. Indeed, such side products show bioactivity,72 and their formation could be considered as a potential example of multiple product formation from a single NRPS.
The details and the sequence of the cyclooligomerization reactions that follow the formation of the first dipeptidol and finally lead to the release of the finalized COD product remain to be demonstrated. Both the twin T2 domains and the N- and C-terminal C domains of CODS were proposed to take part in cyclooligomerization, as described in Section 4.6. The N-terminal C1 and the C-terminal C3 domains of fungal CODSs show overall sequence similarity to condensation domains, but their core motifs show substantial variation from the canonical forms.22,57,99 C3 domains are more conserved, with highly recognizable core motifs C2–C5. The core motif C3 that contains the canonical His active site (HHxxDG) is only slightly altered to SHALYDG, and is apparently invariant in all the C3 domains of CODSs. The C3 domains show the highest similarity (∼42% identity) to the C-terminal C domains of the aureobasidin A1 synthetase from Aureobasidium pullulans (ACJ04424) and the cyclosporine synthetase of Tolypocladium inflatum (CAA82227). These C-terminal C domains are predicted to catalyze macrocyclization by ester (aureobasidin synthetase) or peptide bond formation (cyclosporine).114,115 On the other hand, the C3 domains of CODS exhibit very low similarity to the C-terminal C domains of those bacterial NRPSs which catalyze macrocyclization by ester bond formation during rapamycin, FK506, FK520 and meridamycin biosynthesis, and display negligible similarity to bacterial TE domains that catalyze cyclooligomerization during enterobactin, bacillibactin, valinomycin and cereulide synthesis. The C1 domains of CODSs are more divergent, with only a variant of the core motif C3 (SHxxVD) recognizable. The BbBEAS and the TaCODS C1 domain active site signatures (HxxxD and S
xxVD, respectively) even lack the His residue which is considered to be essential for condensation reactions.22,113 The C1 domains show no close similarity to any particular group of C domains outside CODSs. The divergence of the C1 and C3 domains of CODSs from the canonical amide bond-forming C domains of other NRPSs might be a consequence of their suggested role in the cyclooligomerization process, including the recursive ester bond-forming ligations and the product-releasing cyclization reaction. However, there is no experimental evidence to support the hypothetical functions of either the C1 or C3 domains in cyclodepsipeptide synthesis to date.
T2a–Sp2–NMeAA–HA + T2b–Sp3–NMeAA–HA → T2a–SHp2 + T2b–Sp3–[NMeAA–HA]2 | (6) |
![]() | ||
Fig. 2 Models for COD biosynthesis via stepwise assembly (Linear model) or oligomerization (Parallel model). Dark grey spheres represent 2-hydroxycarboxylic acid moieties; light grey spheres symbolize amino acid moieties. See text for details. |
Early release of the enzyme-bound tetrapeptidols in the form of cyclic tetradepsipeptide products was observed in vitro in PF1022 synthesis (W. Weckwerth, Doctoral Thesis, TU Berlin, 1998). The same truncated compounds with the structures cyclo(D-Lac–N-Me-L-Leu–D-Lac–N-Me-L-Leu), cyclo(D-Lac–N-Me-L-Leu–D-PheLac–N-Me-L-Leu), and cyclo(D-PheLac–N-Me-L-Leu–D-PheLac–N-Me-L-Leu) were also found to be formed during fermentation of the wild-type producer strain.
After the tetrapeptidol stage, repetition of reactions (2)–(5) leads to a synthetase with a dipeptidol intermediate anchored at one of the T2 domains, which could be ligated by the C1 and/or the C3 domains with the tetrapeptidol intermediate parked on the other T2 domain. This leads to the formation of the hexapeptidol intermediate (reaction (7a)).
T2a–Sp2–NMeAA–HA + T2b–Sp3–[NMeAA–HA]2 → T2a–SHp2 + T2b–Sp3–[NMeAA–HA]3 | (7a) |
In case of octapeptidols such as PF1022, a further dipeptidol assembly and ligation cycle is envisioned. After the appropriate number of recursive intermolecular ligations (n = 3 for cyclohexadepsipeptides and n = 4 for cyclooctadepsipeptides), the linear oligomer might fold back and become a substrate for the intramolecular cyclization that releases the final cyclooligomer product (equation (7b)). This product release reaction is analogous to that catalyzed by cyclizing C or TE domains, and has been proposed to be carried out by one or both of the C1 and the C3 domains.91,110
T2b–Sp3–[NMeAA–HA]n → T2b–SHp3 + COD | (7b) |
An alternative mechanism to the classic “parallel” model of cyclooligomerization would involve the buildup of cyclooligomer depsipeptides on the enzyme by stepwise iterative condensations (Fig. 2). During this “linear” mechanism, dipeptidol formation on the T2 domains would be followed by condensation with D-Hiv presented on the T1 domain, catalyzed by either or both the C1 or C3 domains, leading to a tripeptidol. The tripeptidol would then be condensed with the N-Me-amino acid on the T2 domain to form the tetrapeptidol. The process would continue in a stepwise manner until the appropriate chain length is achieved and synthesis is terminated by cyclization as catalyzed by either or both of the C1 or C3 domains. In this model, the presence of the two copies of the T2 domains would not be a structural requirement of COD biosynthesis, and might only increase the turnover of the enzyme, a mechanism which has a precedent in polyunsaturated fatty acid biosynthesis.116,117
Experimental evidence for the “parallel” model is limited at the moment, and does not conclusively rule out the “linear” mechanism. The enniatin synthetase was shown to be a monomer,110 and thus the active sites on a single synthetase should be sufficient for the formation of a COD, excluding the possibility that three synthetase subunits would each contribute one dipeptidol to the final product. Performic acid release of products after a brief in vitro condensation reaction with the purified FeESYN enniatin synthetase yielded only the dipeptidol and the tetrapeptidol,84 supporting the “parallel” mechanism. However, product yield in these pioneering experiments was extremely low. Therefore the formation of tri- and/or pentapeptidols might have gone undetected if synthesis of these species was rate limiting compared with their condensation with amino acids to yield the tetra- and hexapeptidols. Further evidence for the “parallel” mechanism comes from mass spectra of the products of PF1022 fermentations, in which only the even-numbered truncated products (diketomorpholines, tetra- and hexadepsipeptides) could be detected.61 Further investigations by CODS domain engineering, and Fourier-transform mass spectrometric detection and identification of the enzyme-bound intermediates promises to shed more light on this interesting process.118,119
![]() | ||
Fig. 3 Phylogenomic analysis of CODSs. The sequences of the C1, C2, and C3 domains of the CODSs were concatenated, a multiple sequence alignment was created in VectorNTI, and bootstrapped trees were calculated in ClustalX with the neighbor-joining method using 1000 repeats. The phylogram was plotted with NJPlot using C1C2C10_Aur, the concatenated sequences of the C1, C2 and C10 domains of the aureobasidin synthetase,114 as the outgroup. The scale shows the number of substitutions per site, and significant (>500) bootstrap values are indicated near the forks. (3×) and (4×) indicates the cyclotrimeric or cyclotetrameric nature of the known COD products, respectively. |
![]() | ||
Fig. 4 Cyclooligomerization during COD biosynthesis in bacteria vs. fungi. See text for details. |
![]() | ||
Fig. 5 Proposed biosynthesis of angolide, a pseudo-cyclodimeric fungal natural product. One of the D-Hiv moieties was arbitrarily assigned as the starter unit. The picture shows the growing depsipeptide chain as the appropriate intermediates anchored on the T domains. See text for details. |
The Zocher lab described the purification and enzymatic characterization of a 53 kDa “D-hydroxyisovalerate dehydrogenase” from Fusarium sambucinum.128–130 This enzyme was shown to catalyze the reversible interconversion of ketoisovalerate and D-Hiv, with high enantioselectivity in an ordered bi-bi kinetic mechanism. The sequential order of the reaction was found to be identical to that of ketopantoate reductases from the 6-phosphogluconate dehydrogenase superfamily. Ketopantoate reductases (E.C. 1.1.1.169) catalyze the NADPH-dependent stereospecific reduction of ketopantoate to D-pantoate in vitamin B5 biosynthesis.131 The F. sambucinumD-Hiv dehydrogenase displayed high substrate specificity, and was specific for NADP+. However, the sequence of the protein and its encoding gene have not been reported.
The BbBEAS beauvericin synthetase locus of Beauveria bassiana was found to contain a gene (kivr) encoding a putative protein with a GxGxxGxxxA NAD(P)H-binding signature and high similarity to COG1893 ketopantoate reductases.132 The predicted KIVR protein had a deduced MW = 51493 Da, in good agreement with the size of the Fusarium sambucinumD-Hiv dehydrogenase enzyme. KIVR was predicted to show a similar secondary structure to those of ketopantoate reductases. It was also predicted to share a Glu-Asn-Lys active site triad architecture with them, as well as key conserved amino acids involved in substrate and product orientation. No similar gene was clustered with the BbBSLS bassianolide synthetase of the same strain. KIVR was expected to supply D-Hiv for the biosynthesis of beauvericin and perhaps bassianolide: accordingly, disruption of the kivr gene in the genome of B. bassiana abrogated not only the production of beauvericin, but also that of bassianolide. Chemical complementation of the mutant by supplementing the fermentation medium with D-Hiv restored the production of both CODs. Thus, KIVR is the only enzyme that can produce D-Hiv in B. bassiana for the biosynthesis of both beauvericin and bassianolide, thereby representing a functional crosstalk between the two COD biosynthetic systems of the strain.132
Immediately upstream of the FolESYN enniatin synthetase of Fusarium oxysporum f. sp. lycopersici is a divergently transcribed gene (FOXG_11846) that encodes a putative ketoisovalerate reductase which is 61% identical and 76% similar to the B. bassiana KIVR. The respective predicted protein FOXG_11846.2 was erroneously annotated in a C-terminally truncated form, but this shortened version of 367 amino acids was successfully expressed in E. coli, although mostly in the form of inclusion bodies (P. Grzesik, Diploma Thesis, TU Berlin, 2009). The N-terminally His-tagged construct of about 43 kDa showed KIV-dependent NADPH-consumption with a Km of 2.5 mM, compared to 0.2 mM for the 53 kDa dehydrogenase isolated from F. sambucinum.
The uncharacterized reductase domain appended to the C-terminus of the XsBSLS bassianolide synthetase of Xylaria sp. (amino acids 3136–3546) also shows 25% identity and 43% similarity to KIVR. Both FOXG_11846 and the R domain of XsBSLS retain the NADP+-binding site and the Glu-Asn-Lys active site triad architecture of the B. bassiana KIVR and the related ketopantoate reductases from the 6-phosphogluconate dehydrogenase superfamily, and likely supply D-Hiv or similar D-2-hydroxycarboxylic acids for their cognate CODS partners.
In contrast, the putative keto(phenyl)propionate reductase BD105415 which is clustered with the RsPFSYN of Rosellinia sp. displays a very low (10%) identity to the KIVR proteins. The Glu-Asn-Lys active-site triad of the KIVR sequences or the ketopantoate reductases from the 6-phosphogluconate dehydrogenase superfamily are not retained in BD105415, nor are the additional residues involved in the stabilization of the substrate or the product. Instead, BD105415 reveals significant similarity to lactate dehydrogenases (COG1052) within the D-isomer-specific 2-hydroxyacid dehydrogenase superfamily, with an NAD(P)+-binding Rossmann fold (cl09931) at the C-terminal half of the protein. Similarly, the Trichoderma CODSs are also clustered with putative NAD(P)+-binding, D-isomer-specific 2-hydroxyacid dehydrogenases (T. virens: e_gw1.82.328.1, T. atroviridae: fgenesh1_pm.contig_27_#_418 and Triat1.e_gw1.1.3874.1). Interestingly, while the T. virens e_gw1.82.328.1 dehydrogenase and the T. atroviridae Triat1.e_gw1.1.3874.1 enzymes are 86% identical at the protein level, the two T. atroviridae dehydrogenase protein sequences, both bordering the same CODS, share only 24% identity.
Biosynthesis-guided purification studies in the PF1022 producer led to the purification of a 38 kDa D-phenyllactate dehydrogenase (W. Weckwerth, Doctoral Thesis, TU Berlin, 1998). In these studies, the phenylpyruvate dependence of COD biosynthesis was monitored in a reconstituted reaction system containing the PF1022 synthetase, Leu, ATP, SAM, and NADPH. The D-phenyllactate dehydrogenase enzyme was purified about 5000-fold in 7 steps, and shown to reduce phenylpyruvate with a Km = 38 µM. Besides phenylpyruvate, p-hydroxyphenyl-pyruvate (Km = 45 µM) and 2-ketoisocaproate (Km = 53 µM) were also accepted as substrates. Results from gel filtration experiments indicated a dimeric structure. Internal tryptic peptides of the purified enzyme showed some similarity to BD105415 (predicted size 36470 Da).
Genes encoding putative regulatory proteins containing the Gal4-like Zn2Cys6 binuclear cluster DNA-binding domain (Smart SM00066, InterPro IPR001138) were found to be clustered with BbBEAS (orf1),22 and FolCODS (FOXG_11849 and FOXG_11859). The BbBSLS bassianolide synthetase cluster also encodes a putative Gal4-like transcriptional regulator (ORF5) and the predicted GTPases ORFs 1 and 4.57 A predicted Gal4-like transcription factor (gw1.82.211.1) is adjacent to the T. virens CODS, while the T. atroviridae CODS is clustered with a putative TFIIS-type zinc finger transcription factor (Triat1.e_gw1.1.2849.1).
The nrpsxy gene encoding the XsBSLS bassianolide synthetase of Xylaria sp. was found to be clustered with the efxy gene encoding a putative major facilitator superfamily (MFS) transporter with significant similarity to other MFS transporters encoded in many fungal genomes.55 The two Trichoderma CODSs are also clustered with hypothetical MFS transporters (T. virens: fgenesh1_pg.82_#_180; T. atroviridae: Triat1.e_gw1.1.3461.1). The Fusarium oxysporum f. sp. lycopersici FolCODS is clustered with FOXG_11845 which encodes a predicted ATP binding cassette (ABC) multidrug transporter. No transport-related putative proteins were found to be encoded in the sequenced regions of the beauvericin or the bassianolide clusters of Beauveria bassiana.22,57
Since the attempts to obtain soluble single domains of the FeESYN in E. coli were not successful, the M2 methyltransferase domain was overexpressed in yeast, yielding the desired protein in soluble fraction. The M2 domain (1.3 kbp) was cloned in the E. coli–S. cerevisiae shuttle vector pYEXTHS-BN with an N-terminal His6-tag and C-terminal strep II fusion peptide. Cofactor binding was demonstrated by photoaffinity labeling134 and by saturation transfer difference (STD)-NMR spectroscopy under equilibrium conditions, establishing the distance and orientation of enzyme-bound SAM relative to the binding site. The kinetic constants for binding of the cofactor and the substrate were also determined, and were shown to be similar to those of the M2 domain embedded in FeESYN, indicating that the dissected domain was correctly folded upon heterologous expression. The specificity of the methyltransferase was investigated using N-acetylcysteamine thioesters (SNAC) of L-Leu, L-Ile, L-Phe, L-Val and D-Val. Surprisingly, all tested amino acids except D-valine yielded methylated products at similar rates, as detected by radioactive labeling and MALDI-TOF mass spectrometry. Although the M2 domain accepts only amino acids with an L-configuration, it apparently has a widened substrate tolerance, even for substrates which had previously been shown not to be substrates for the full-length enniatin synthetase, such as L-Phe.100
Heterologous expression of CODS, and heterologous production of CODs in strains that are easier to manipulate genetically than the native fungal producers will facilitate the enzymatic characterization of CODS and their engineered variants, and will promote the combinatorial biosynthesis of novel CODs.
Enniatin | R1 | R2 | R3 | R4 | R5 | R6 | M1 | M2 | M3 | First isolated from | Ref. |
---|---|---|---|---|---|---|---|---|---|---|---|
a Enniatin E is produced by the organism as a mixture of the two listed diastereomers that were not named separately.24 | |||||||||||
A | iPr | iPr | iPr | sBu | sBu | sBu | Me | Me | Me | Fusarium orthoceras var. enniatinum ETH 1523 and F. scirpi ETH 1536 | 152 |
A1 | iPr | iPr | iPr | iPr | sBu | sBu | Me | Me | Me | Fusarium roseum acuminatum | 153 |
B | iPr | iPr | iPr | iPr | iPr | iPr | Me | Me | Me | Fusarium spp. ETH 4363 and ETH 1574 | 152 |
B1 | iPr | iPr | iPr | sBu | iPr | iPr | Me | Me | Me | Fusarium roseum acuminatum | 153 |
B2 | iPr | iPr | iPr | iPr | iPr | iPr | H | Me | Me | Fusarium avanaceum | 33 |
B3 | iPr | iPr | iPr | iPr | iPr | iPr | H | H | Me | Fusarium avanaceum | 33 |
C | iPr | iPr | iPr | iBu | iBu | iBu | Me | Me | Me | Fusarium spp. ETH 4363 and ETH 1574 | 152 |
D (= B4) | iPr | iPr | iPr | iBu | iPr | iPr | Me | Me | Me | Fusarium sp. FO-1305 | 24 |
Ea | iPr | iPr | iPr | iBu | iPr | sBu | Me | Me | Me | Fusarium sp. FO-1305 | 24 |
iPr | iPr | iPr | iBu | sBu | iPr | ||||||
F | iPr | iPr | iPr | iBu | sBu | sBu | Me | Me | Me | Fusarium sp. FO-1305 | 24 |
G | iPr | iPr | iPr | iPr | iBu | iBu | Me | Me | Me | Halosarpheia sp. strain 732 | 47 |
H | sBu | iPr | iPr | iPr | iPr | iPr | Me | Me | Me | Verticillium hemipterigenum BCC 1449 | 144 |
I | sBu | sBu | iPr | iPr | iPr | iPr | Me | Me | Me | Verticillium hemipterigenum BCC 1449 | 144 |
MK 1688 | sBu | sBu | sBu | iPr | iPr | iPr | Me | Me | Me | Verticillium hemipterigenum BCC 1449 | 144 |
J1 | iPr | iPr | iPr | Me | iPr | iPr | Me | Me | Me | Fusarium sp. strain F31 | 142 |
J2 | iPr | iPr | iPr | iPr | sBu | Me | Me | Me | Me | Fusarium sp. strain F31 | 142 |
J3 | iPr | iPr | iPr | iPr | Me | sBu | Me | Me | Me | Fusarium sp. strain F31 | 142 |
K1 | iPr | iPr | iPr | Et | iPr | iPr | Me | Me | Me | Fusarium sp. strain F31 | 142 |
L | iPr | iPr | hy-sBu | iPr | iPr | iPr | Me | Me | Me | Unidentified fungus (BCC 2629) | 154 |
M1 | iPr | sBu | hy-sBu | iPr | iPr | iPr | Me | Me | Me | Unidentified fungus (BCC 2629) | 154 |
M2 | iPr | hy-sBu | sBu | iPr | iPr | iPr | Me | Me | Me | Unidentified fungus (BCC 2629) | 154 |
N | sBu | sBu | hy-sBu | iPr | iPr | iPr | Me | Me | Me | Unidentified fungus (BCC 2629) | 154 |
O1 | iPr | iPr | sBu | iBu | iPr | iPr | Me | Me | Me | Verticillium hemipterigenum BCC 1449 | 46 |
O2 | iPr | iPr | sBu | iPr | iBu | iPr | Me | Me | Me | Verticillium hemipterigenum BCC 1449 | 46 |
O3 | iPr | iPr | sBu | iPr | iPr | iBu | Me | Me | Me | Verticillium hemipterigenum BCC 1449 | 46 |
P1 | iPr | iPr | iPr | hy-Et | iPr | iPr | Me | Me | Me | Fusarium acuminatum (Gibberella acuminata) | 143 |
P2 | iPr | iPr | iPr | hy-Et | iBu | iPr | Me | Me | Me | Fusarium acuminatum (Gibberella acuminata) | 143 |
The cylcooctadepsipeptides of the PF1022 family are produced by Mycelia sterilia (Rosellinia sp.), with PF1022A as the main metabolite.61 The PF1022 congeners consist of four L-Leu residues, but differ in their D-hydroxycarboxylic acid content. Thus, PF1022A-D and F differ in the number of D-PheLac and D-Lac residues occupying the hydroxycarboxylic acid positions (Table 4). In contrast, PF1022E and PF1022-202 both contain two D-Lac, but with one or both D-PheLac positions replaced by p-hydroxy-D-PheLac.
R1 | R2 | R3 | R4 | |
---|---|---|---|---|
PF 1022A | Me | Bzl | Me | Bzl |
PF 1022B | Bzl | Bzl | Bzl | Bzl |
PF 1022C | Me | Bzl | Bzl | Bzl |
PF 1022D | Me | Me | Me | Bzl |
PF 1022E | Me | Bzl-p-OH | Me | Bzl |
PF 1022F | Me | Me | Me | Me |
PF 1022-202 | Me | Bzl-p-OH | Me | Bzl-p-OH |
Beauveria bassiana ARSEF 4122 produces beauvericin A and B, with (2R,3S)-2-hydroxy-3-methylpentanoate (D-2-hydroxy-3-methylvalerate, D-Hmv) residues replacing one or two D-Hiv residues. These analogs were evaluated in an insecticidal assay.138 Beauvericins D (L-Phe replacing one N-methyl-L-Phe residue), E (L-Leu instead of one N-Me-L-Phe residue) and F [(2R)-2-hydroxy-4-methylpentanoate instead of one D-Hiv] were isolated from Beauveria sp. FKI-1366 and shown to display antifungal activity.28,29
Precursor-directed biosynthesis introduces added complexity during COD analog production. First, amino acid precursor analogs may incorporate directly to the amino acid positions in the COD, or may be converted to the corresponding D-2-hydroxycarboxylic acid and thus may also replace the hydroxycarboxylic acid constituents of the COD. Further, each precursor is used several times during the iterative assembly of the monomer units. Thus, incorporation of a precursor analog leads to the production of a COD analog family in which 1, 2 or all 3 (trimeric CODs) or 1, 2, 3 or all 4 (tetrameric CODs) of the positions for that substrate are replaced by the analog. Further, when two molecules of the same precursor analog incorporate into a tetrameric COD, two isomeric products are produced (one where the replacements took place in adjoining monomers, and another where the modified and the native monomers are alternating), due to the possibility of circular permutation.
Precursor-directed biosynthesis has been assessed by Zocher and coworkers using the enniatin producers Fusarium scirpi and F. sambucinum.140 A small set of radioactively labeled hydroxycarboxylic acids (DL-2-hydroxy-n-valeric acid, D-2-hydroxy-3-methyl-n-valeric acid, DL-hydroxybutyric acid [DL-Hbu], and D-Lac) and L-amino acids (L-2-amino butyric acid [L-Abu], L-Ala, L-Cys, L-Thr, L-Ser and L-allylglycine) were separately fed in a single dose (10 mM, final concentration) to the cultures after 72 h of fermentation. The cultivation was continued for another two days. The formation of enniatin analogs was analyzed by HPLC, mass spectrometry and NMR spectroscopy. Amongst the hydroxycarboxylic acids, formation of product analogs could only be observed with D-Lac and DL-Hbu. In contrast, the amino acids L-Ala, L-Abu, L-Ser and L-Thr all yielded new enniatins. The “unnatural” all-D-Lac enniatin was found to have anthelminthic properties.141 Subsequently, L-Ala, L-Thr and L-Abu-containing natural enniatins (enniatin J1-3,K, P1/2) have also been isolated from Fusarium sp. strain F31 and Fusarium acuminatum (Gibberella acuminata).142,143
Precursor-directed biosynthesis was also used to produce enniatin analogs, using the insect pathogenic fungus Verticillium hemipterigenum BCC 1449 as the producing organism.144 This strain biosynthesizes enniatins B (trimer of D-Hiv–L-Val), B4 (one L-Leu and two L-Val as the amino acid constituents), H (one D-Hmv and two D-Hiv as the hydroxycarboxylic acids), and I (two D-Hmv and one D-Hiv as the hydroxycarboxylic acid constituents, Table 3). Upon feeding L-Leu, the production of enniatin B4 was increased, and the fermentations also yielded enniatins G (two L-Leu and one L-Val as the amino acids) and minor amounts of enniatin C (three L-Leu as the amino acid constituents). Feeding L-Ile increased the production of enniatins H and I, and led to the production of the new enniatin analog MK1688 (trimer of D-Hmv–L-Val). Thus, L-Leu is readily accepted by the amino acid-activating A2 domain of the V. hemipterigenum enniatin synthetase in vivo, but not used as a precursor for the hydroxycarboxylic acid positions in enniatin. Conversely, L-Ile serves as an alternative substrate for D-hydroxycarboxylic acid biosynthesis, and for the subsequent incorporation into enniatin by the hydroxycarboxylic acid-activating A1 domain. However, L-Ile is apparently not utilized in vivo as an alternative amino acid precursor by the CODS. All the isolated enniatin analogs were evaluated for their antiplasmodial, antimycobacterial, and cancer cell cytotoxic activities.
Nilanonta et al.15 have used the hypocrealean entomopathogen Paecilomyces tenuipes BCC 1614 to produce beauvericin analogs (Fig. 6). Feeding L-Ile (2S,3S) or D-allo-Ile (2R,3S) led to the production of beauvericins A, B and C with one, two or all three D-Hiv positions replaced by (2R,3S)-Hmv. Feeding D-Ile (2R,3R) or L-allo-Ile (2S,3R) provided allo-beauvericins A, B, and C, featuring one, two or three (2R,3R)-Hmv residues. These experiments are congruent with the conversion of all four Ile diastereomers to the 2-ketocarboxylic acid, and to the stereospecific reduction of this intermediate to the corresponding (2R)-hydroxycarboxylic acid, with retention of configuration at the 3-position. Both (2R,3S)- and (2R,3R)-Hmv are accepted as alternative substrates by the hydroxycarboxylic acid-activating A1 domain of the P. tenuipes beauvericin synthetase in vivo. Conversely, none of the Ile diastereomers are acceptable in vivo substrates to replace L-Phe in beauvericin. The new beauvericin analogs showed similar antimycobacterial, antiplasmodial and cancer cell antiproliferative activities to that of beauvericin.
![]() | ||
Fig. 6 Precursor-directed biosynthesis of beauvericin analogs. |
Precursor-directed biosynthesis was also applied to produce beauvericin analogs with Beauveria bassiana ATCC 7159 (Fig. 6), using 30 potential precursor analogs of D-Hiv and L-Phe.145 Feeding L-Ile afforded beauvericins A, B and C: similar experiments yielded the same products in Paecilomyces tenuipes.144 However, the BbBEAS beauvericin synthetase proved to be rather fastidious in vivo, with only a few other precursor analogs accepted. Thus, D-Hiv could be replaced only by (2R)-2-hydroxybutyric acid (D-Hbu) to yield beauvericins G1, G2 and G3 featuring one, two or three D-Hbu moieties. As expected, the (2S)-isomer (L-Hbu) was not accepted by the system. L-Phe could only be substituted by 2-fluoro or 3-fluoro analogs of Phe to yield the beauvericin I1–3 and H1–3 series, respectively. Both the L and D isomers of these amino acid precursor analogs were readily utilized by the cells, but the synthetase itself seemed to be stereospecific, as the final beauvericin analogs contained amino acids with only the L configuration. This suggested that the substrates underwent epimerization in the cells prior to incorporation into the COD. The isolated novel beauvericin analogs were evaluated for cancer cell antiproliferative and cell motility inhibitory activities. These two bioactivities were affected to a different degree by the structural changes, suggesting that it might be possible to separately optimize cytotoxicity and haptotaxis inhibition in future beauvericin analogs.145
Precursor-directed biosynthesis of unnatural PF1022 derivatives in Mycelia sterilia (Rosellinia sp.) was only successful with p-nitro-PheLac and p-nitro-L-Phe (this latter precursor analog undergoes in vivo deamination and ketoreduction to p-nitro-PheLac). The feeding of 10–70 mM of these precursors yielded up to 40% of PF 1022-268 (the monosubstituted p-nitro-PheLac derivative) and up to 10% of the desired disubstituted p-nitro-PheLac derivative, PF 1022-220 (the yield of PF 1022A = 100%). PF 1022-220 constitutes a potentially useful intermediate that might significantly simplify the production process for emodepsid, an important semisynthetic anthelminthic agent.70 However, the low yields of precursor-directed biosynthesis currently prohibit the scale-up of this process to industrial production (W. Weckwerth, Doctoral Thesis, TU Berlin, 1998, and M. Krause, Doctoral Thesis, TU Berlin, 1998).
As these examples show, the success of precursor-directed biosynthesis experiments in CODS systems is currently not predictable. Substrate promiscuity does not derive merely from substrate recognition and activation by the A domains. Rather, successful production of unnatural CODs requires correct processing of the precursors and intermediates by the C domains and the subsequent modifying enzymes. The products should also be acceptable for the COD export system, and the unnatural CODs should not be overly toxic to the producer cells. More knowledge and expertise has to be gathered to make precursor-directed biosynthesis of CODs more predictable, reliable, and economical on the industrial scale.
Xue et al. have used a kivr mutant of Beauveria bassiana ATCC 7159 for the mutasynthetic production of novel beauvericin analogs.132 This strain lacks ketoisovalerate reductase, and thus it is unable to produce D-Hiv or similar branched-chain 2-hydroxycarboxylic acids as precursors for beauvericin biosynthesis, leading to a complete block in beauvericin (and bassianolide) biosynthesis. From five commercially available 2-hydroxycarboxylic acids (Hbu, DL-Lac, hydroxyisocaproic acid, mandelate, and cyclohexyllactate), only D-Hbu restored COD biosynthesis in B. bassiana, leading to the exclusive and high-titer production of beauvericin G3. This analog has previously been detected during precursor-directed biosynthesis, but in substantially lower yields.145 Feeding synthetic DL-2-hydroxy-3-methylvaleric acid (DL-Hmv) to the kivr mutant strain was found to support the exclusive production of the known analog beauvericin C in a good yield. This analog had been previously observed in small amounts in precursor-directed biosynthesis with wild-type beauvericin producer strains.15,145
To further increase the structural variety of beauvericin analogs, Xu et al. have conducted simultaneous feeding of precursor analogs in pairwise combinations using the kivr knockout B. bassiana strain, in a procedure dubbed “combinatorial mutasynthesis” (Fig. 7).132 Such scrambling with two precursor analogs would not have been practical using the wild-type strain, as the presence of the competing native precursors and precursor analogs would have led to a very large number of possible combinations and circular permutations along the COD macrocycle. Such a complex product mixture would have been challenging to separate, and each analog might have been present only in minor amounts. In contrast, combinatorial mutasynthesis significantly simplified product profiles: the fed hydroxycarboxylic acids completely substituted the D-Hiv positions of beauvericin, while the Phe analogs replaced 0, 1, 2, or all 3 Phe in the products. To demonstrate this principle, the D-Hiv analogs D-Hbu and DL-Hmv, and the Phe analogs 3-fluoro-L-Phe and 2-fluoro-L-Phe, whose acceptability to this strain had already been shown,132,145 were used for this study. Combinatorial mutasynthesis with these four precursor analogs yielded 14 new beauvericin analogs belonging to five novel series. Importantly, in several product analogs, all hydroxycarboxylic acid and amino acid positions of beauvericin were completely replaced by the fed mutasynthons. Nine isolated analogs and three beauvericin analog mixtures that could not be separated under standard conditions were evaluated for cancer cell antiproliferative and cell motility inhibitory activities. As before, variation of the two activities due to the structure changes was not strictly parallel, indicating that more drastic structural alterations of the beauvericin scaffold may help to disconnect the antiproliferative and anti-haptotactic activities.
![]() | ||
Fig. 7 Mutasynthesis and combinatorial mutasynthesis of beauvericin analogs. |
![]() | ||
Fig. 8 Total biosynthesis of COD analogs. Incorporation of different synthetic 2-hydroxycarboxylic acids (only the side chains shown), replacing the side chains (represented as small circles) in A. enniatin, and B. PF 1022. The percentages describe the enzyme activity in kcat,app in comparison to the natural substrate (enniatin: D-Hiv; PF1022: D-PheLac for the aromatic and D-Lac for the aliphatic precursors, respectively). |
To learn more about the substrate specificity of the enniatin CODS and to create a bigger library of new derivatives by chemoenzymatic synthesis or total biosynthesis, various hydroxycarboxylic acids with linear, branched and cyclic side chains – up to seven carbon atoms and various functional groups, e.g. halogens, hydroxy and thioether groups – were chemically synthesized and tested in an in vitro assay with the purified ESYN from F. oxysporum. Surprisingly, some of the hydroxycarboxylic acid substrates proved to be as good substrates as D-Hiv. Thus, D-Hiv could be efficiently replaced by D-chlorolactate, D-bromolactate, D-propargyl lactate, and D-Hbu, whereas the extension of the aliphatic side chain decreased product yield (Fig. 8A). From these findings, the binding pocket is proposed to accommodate alkyl chain residues with a minimum of two carbon atoms (D-Hbu), but with a maximum of three carbons in linear and four carbons in branched chains. No substrate activation was found for polar, ionic or aromatic hydroxycarboxylic acid side chains.89
Similar to that with the enniatin synthetase FoESYN, the purified RsPFSYN was also used to perform in vitro total biosynthesis. The naturally found product distributions in fermentations could be reproduced in vitro with the natural substrates.61 Since the observed substrate spectrum of RsPFSYN includes two sterically and electronically very different hydroxycarboxylic acids, D-Lac and D-PheLac, a certain substrate promiscuity was expected from this enzyme. Various hydroxycarboxylic acids were synthesized and tested with RsPFSYN for the enzymatic assembly of PF1022 analogs, with the range of synthetic substrates extended to >40 aromatic and aliphatic hydroxycarboxylic acids. The results showed that a large variety of aliphatic and aromatic hydroxycarboxylic acids were indeed acceptable as substrates (Fig. 8B). A strong correlation has been observed between the substrate tolerances of FoESYN and RsPFSYN towards aliphatic hydroxycarboxylic acids. Among the aromatic PF1022 derivatives obtained, the most interesting ones contained heterocycles (e.g. thiophene), or functionalized phenyl rings (e.g. a perfluorinated analog). While no clear rules for the substrate specificity of RsPFSYN could be deduced, the substrate tolerance seemed to increase for aromatic residues with lesser steric demand, or for precursors with decreased rotational freedom at the β-position.90
Overall, a number of truly unnatural enniatins and PF1022 derivatives were generated using in vitro biosynthesis. Such derivatives could facilitate further semi-synthetic modification, for example by Sonogashira coupling at the alkyne functionalities.150 Remarkably, RsPFSYN has an extended substrate spectrum towards aromatic residues compared to FoESYN, but neither of these CODSs is able to accept hydroxycarboxylic acids with polar or charged side chains. Nevertheless, both enzymes display a potential for the generation of large COD libraries, at least in vitro. A significant disadvantage of this chemoenzymatic approach is that only small amounts of CODs are obtained in routine experiments, and scale-up of the reactions is difficult. However, as opposed to precursor-directed biosynthesis and mutasynthesis, in vitro biosynthesis is not limited by substrate uptake or catabolism by the cell, nor by precursor or product toxicity issues.
![]() | ||
Fig. 9 Biosynthesis of PF1022 analogs by precursor supply pathway engineering. |
A | adenylation |
AA | L-amino acid |
ABC | ATP binding cassette |
Abu | 2-aminobutyric acid |
ACAT | acyl-CoA:cholesterol acyltransferase |
AMP | adenosine monophosphate |
ATP | adenosine triphosphate |
B. | Beauveria |
BEAS | beauvericin synthetase |
BSLS | bassianolide synthetase |
C | condensation |
CoA | coenzyme A |
COD | cyclooligomer depsipeptide |
CODS | cyclooligomer depsipeptide synthetase |
Cy | cyclization |
E | epimerization |
ESYN | enniatin synthetase |
F. | Fusarium |
G. | Gibberella |
H. | Hirsutella |
HA | D-hydroxycarboxylic acid |
Hbu | 2-hydroxybutyric acid |
Hiv | 2-hydroxyisovaleric acid |
HIV | human immunodeficiency virus |
Hmv | 2-hydroxy-3-methylvaleric acid |
HPLC | high-performance liquid chromatography |
I. | Isaria |
Ile | isoleucine |
KIVR | ketoisovalerate reductase |
KR | ketoreductase |
Lac | lactic acid |
Leu | leucine |
M | methylation |
mAb | monoclonal antibody |
MDR | multidrug resistance |
NADP | nicotinamide adenine dinucleotide phosphate |
NRPS | nonribosomal peptide synthetase |
Ox | oxidation |
P. | Paecilomyces |
PFSYN | PF1022 synthetase |
Pgp | P-glycoprotein |
Phe | phenylalanine |
PheLac | phenyllactic acid |
PPi | pyrophosphate |
Pro | proline |
R | reductase |
S. | Saccharomyces |
SAH | S-adenosylhomocysteine |
SAM | S-adenosyl-L-methionine |
T. | Trichoderma |
T | thiolation |
TE | thioesterase |
TLC | thin-layer chromatography |
V. | Verticillium |
Val | valine |
This journal is © The Royal Society of Chemistry 2011 |